___

• [1] Tugrak, M., Gul, H. İ., & Gulcin, İ. “Acetylcholinesterase inhibitory potencies of new pyrazoline derivatives,” Journal of Research in Pharmacy, (2020) 24(4).
• [2] Gulcin, İ., Petrova, O. V., Taslimi, P., Malysheva, S. F., Schmidt, E. Y., Sobenina, L. N., ... & Sujayev, A. R. “Synthesis, Characterization, Molecular Docking, Acetylcholinesterase and α‐Glycosidase Inhibition Profiles of Nitrogen‐Based Novel Heterocyclic Compounds,” ChemistrySelect, (2022), 7(19), e202200370.
• [3] Bilginer, S., Gul, H. I., Anil, B., Demir, Y., & Gulcin, I. “Synthesis and in silico studies of triazene‐substituted sulfamerazine derivatives as acetylcholinesterase and carbonic anhydrases inhibitors,” Archiv der Pharmazie, (2021) 354(1), 2000243.
• [4] Craig, L. A., Hong, N. S., & McDonald, R. J. “Revisiting the cholinergic hypothesis in the development of Alzheimer's disease.” Neuroscience & Biobehavioral Reviews, (2011) 35(6), 1397-1409.
• [5] Gülçin, İ., Bingöl, Z., Taslimi, P., Gören, A. C., Alwasel, S. H., & Tel, A. Z. “Polyphenol contents, potential antioxidant, anticholinergic and antidiabetic properties of mountain mint (Cyclotrichium leucotrichum).” Chemistry & Biodiversity, (2022) 19(3), e202100775.
• [6] Burmaoglu, S., Yilmaz, A. O., Polat, M. F., Kaya, R., Gulcin, İ., & Algul, O. “Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase, and α-glycosidase inhibitors.” Bioorganic chemistry, (2019) 85, 191-197.
• [7] Aksu, K., Akıncıoğlu, H., Akıncıoğlu, A., Goksu, S., Tuemer, F., & Gulcin, I. “Synthesis of novel sulfonamides incorporating phenethylamines and determination of their inhibition profiles against some metabolic enzymes.” Archiv der pharmazie, (2018) 351(9), 1800150.
• [8] [8] Turkan, F., Cetin, A., Taslimi, P., & Gulçin, İ. “Some pyrazole derivatives: Potent carbonic anhydrase, α‐glycosidase, and cholinesterase enzyme inhibitors.” Archiv der pharmazie, (2018) 351(10), 1800200.
• [9] Vitaku, E., Smith, D. T., & Njardarson, J. T. “Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals: mini perspective.” Journal of medicinal chemistry, (2014). 57(24), 10257-10274.
• [10] Kerru, N., Gummidi, L., Maddila, S., Gangu, K. K., & Jonnalagadda, S. B. “A review of recent advances in nitrogen-containing molecules and their biological applications.” Molecules, (2020) 25(8), 1909.
• [11] Ellman, G. L., Courtney, K. D., Andres Jr, V., & Featherstone, R. M.“A new and rapid colorimetric determination of acetylcholinesterase activity.” Biochemical pharmacology, (1961) 7(2), 88-95.
• [12] Garibov, E., Taslimi, P., Sujayev, A., Bingol, Z., Cetinkaya, S., Gulcin, İ., ... & Supuran, C. T. “Synthesis of 4, 5-disubstituted-2-thioxo-1, 2, 3, 4-tetrahydropyrimidines and investigation of their acetylcholinesterase, butyrylcholinesterase, carbonic anhydrase I/II inhibitory and antioxidant activities.” Journal of enzyme inhibition and medicinal chemistry, (2016) 31(sup3), 1-9.
• [13] Mao, F., Li, J., Wei, H., Huang, L., & Li, X. “Tacrine–propargyl amine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease.” Journal of Enzyme Inhibition and Medicinal Chemistry, (2015) 30(6), 995-1001.
• [14] Taslimi, P., Erden, Y., Mamedov, S., Zeynalova, L., Ladokhina, N., Tas, R., ... & Gulcin, I. “The biological activities, molecular docking studies, and anticancer effects of 1-arylsuphonylpyrazole derivatives.” Journal of biomolecular structure and dynamics, (2021) 39(9), 3336-3346.
• [15] Schrödinger Release Glide; Schrödinger, LLC: New York, NY, USA. (2020-3)
• [16] Nepovimova, E., Uliassi, E., Korabecny, J., Pena-Altamira, L. E., Samez, S., Pesaresi, A., ... & Bolognesi, M. L. “Multitarget drug design strategy: quinone–tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects.” Journal of medicinal chemistry, (2014) 57(20), 8576-8589.
• [17] Brus, B., Kosak, U., Turk, S., Pislar, A., Coquelle, N., Kos, J., ... & Gobec, S. “Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor.” Journal of medicinal chemistry, (2014) 57(19), 8167-8179.
• [18] Işık, M. “The binding mechanisms and inhibitory effect of intravenous anesthetics on AChE in vitro and in vivo: kinetic analysis and molecular docking.” Neurochemical research, (2019) 44(9), 2147-2155.
• [19] Ozgun, D. O., Yamali, C., Gul, H. I., Taslimi, P., Gulcin, I., Yanik, T., & Supuran, C. T. “Inhibitory effects of isatin Mannich bases on carbonic anhydrases, acetylcholinesterase, and butyrylcholinesterase.” Journal of enzyme inhibition and medicinal chemistry, (2016) 31(6), 1498-1501.
• [20] Aksu, K., Topal, F., Gulcin, I., Tümer, F., & Göksu, S. “Acetylcholinesterase inhibitory and antioxidant activities of novel symmetric sulfamides derived from phenethylamines.” Archiv der Pharmazie, (2015) 348(6), 446-455.
• [21] Ökten, S., Ekiz, M., Koçyiğit, Ü. M., Tutar, A., Çelik, İ., Akkurt, M., ... & Gülçin, İ. “Synthesis, characterization, crystal structures, theoretical calculations and biological evaluations of novel substituted tacrine derivatives as cholinesterase and carbonic anhydrase enzymes inhibitors.” Journal of Molecular Structure, (2019) 1175, 906-915.